Alabama Patent of the Month – March 2021
Age Related Macular Degeneration is the leading cause of legal blindness in developed countries. Damage to the retina causes a loss of vision in the macula which is the center of your vision. One form of AMD – atrophic – can lead to blindness over the course of many years. The more severe form – neovascular – can result in blindness within 1 year of onset. There is no treatment for atrophic AMD and treatment for neovascular AMD has only 50% efficacy. MacRegan, Inc has designed a topical treatment which can be used for any type and any stage of AMD.
MacRegan’s method involves the use of cell-penetrating peptides (CPP) to effectively deliver the treatment. The treatment is a combination of therapeutic agents like antioxidants and anti-inflammatories, as well as complement inhibitors and neuroprotectors which help to direct the pathway of the treatment. These components are combined with CPPs and administered topically either by eyedrops or a coated contact lens. The treatment works to protect the retina and other components of the eye and prevent damage and scarring which results in blindness. This comprehensive use means it can be used to help prevent AMD from starting, help prevent progression of AMD, and can help with other similar eye disorders as well.
About MacRegen, Inc.
MacRegen is a pre-clinical stage biotechnology company seeking to develop, register, and commercialize first-in-class breakthrough drugs, given alone or in combination with other drugs for the treatment of both dry and wet AMD. The Company has already completed a Preferred Series A round of financing. The Company believes that by targeting the primary etiology of AMD, its new drug Mitia™ may provide unprecedented treatments and prevention of all forms of AMD.
Are you developing new pharmaceuticals ? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.